Podcast appearances and mentions of robert langer

This curated compilation with leaders such as Dr. Etienne, and Dr. Langer, as well as early career professionals and students such as MD-PhD Student Chadwin Hanna, Dr. Ugo, Dr. Maada, and PharmD Student David Ferguson, stitches together the most resonant moments from four interviews recorded in 2020, 2023, 2024, and 2025 with Institute Professor Robert Langer, Sc.D. Across a half-decade marked by pandemic breakthroughs, startup surges, and classroom innovation, Dr. Langer reveals how impact-driven work fuels transformative work at the intersection of bioengineering, academia, and industry.

In this episode, join us for an inspiring conversation again with Dr. Robert Langer, Sc.D. (MIT), as he shares invaluable advice on navigating a successful scientific career and offers a glimpse into the future of nanoscience. In this episode, we explore:Professional Development:Dr. Langer discusses how early-career scientists can build strong, cross-disciplinary partnerships and the key habits and mindsets that helped him transition from bench research to world-changing innovation. He also reflects on how his mentorship approach has evolved over decades, providing guidance to those pursuing leadership roles at the nexus of academia and industry.---Questions:Professional Development:Throughout your career, you've emphasized interdisciplinary collaboration. How can emerging scientists strategically cultivate effective, multidisciplinary partnerships early in their professional journeys?Reflecting on your own professional trajectory, what habits or mindsets do you believe were most crucial in transitioning successfully from scientific inquiry to impactful innovation?How have your mentorship strategies evolved over the years, especially when guiding individuals pursuing leadership roles at the intersection of academia and industry?Considering recent advancements, what novel areas within nanoscience do you find most promising or surprising, particularly those relevant to medical applications?How do you foresee the integration of nanoscience with other disciplines (like artificial intelligence or bioinformatics) reshaping pharmaceutical and biomedical research over the next decade?Could you highlight a recent breakthrough or approach in your lab related to nanoscience that significantly changed your thinking about future therapeutic possibilities?When you developed curricula for math and science education, what core principles guided your approach to ensuring both depth of content and accessibility to diverse learners?How did you balance rigorous scientific accuracy with the practical engagement of students who might not initially be inclined towards STEM subjects?Reflecting on the implementation phase, what strategies or frameworks were most effective in training educators to deliver complex scientific concepts confidently?In your experience, what differentiates a merely effective textbook from one that genuinely inspires students and significantly advances their understanding of scientific concepts?Given your extensive experience, what critical components or features should I emphasize or enhance in my upcoming chemistry  textbooks to better support active learning and critical thinking?Based on your observations, what common pitfalls should be avoided when structuring textbooks intended for advanced high school or undergraduate science courses?Considering current global challenges, how can aspiring scientists and educators ensure their contributions remain impactful, relevant, and grounded?Finally, could you share a recent experience or insight that profoundly influenced your views on education, mentorship, or scientific innovation?----Note: The views of this podcast reflect those of my guest(s) and I.

In medicine, failure can be catastrophic. It can also produce discoveries that save millions of lives. Tales from the front line, the lab, and the I.T. department. SOURCES:Amy Edmondson, professor of leadership management at Harvard Business School.Carole Hemmelgarn, co-founder of Patients for Patient Safety U.S. and director of the Clinical Quality, Safety & Leadership Master's program at Georgetown University.Gary Klein, cognitive psychologist and pioneer in the field of naturalistic decision making.Robert Langer, institute professor and head of the Langer Lab at the Massachusetts Institute of Technology.John Van Reenen, professor at the London School of Economics. RESOURCES:Right Kind of Wrong: The Science of Failing Well, by Amy Edmondson (2023).“Reconsidering the Application of Systems Thinking in Healthcare: The RaDonda Vaught Case,” by Connor Lusk, Elise DeForest, Gabriel Segarra, David M. Neyens, James H. Abernathy III, and Ken Catchpole (British Journal of Anaesthesia, 2022)."Estimates of preventable hospital deaths are too high, new study shows," by Bill Hathaway (Yale News, 2020).“Dispelling the Myth That Organizations Learn From Failure,” by Jeffrey Ray (SSRN, 2016).“A New, Evidence-Based Estimate of Patient Harms Associated With Hospital Care,” by John T. James (Journal of Patient Safety, 2013).To Err is Human: Building a Safer Health System, by the National Academy of Sciences (1999).“Polymers for the Sustained Release of Proteins and Other Macromolecules,” by Robert Langer and Judah Folkman (Nature, 1976).The Innovation and Diffusion Podcast, by John Van Reenen and Ruveyda Gozen. EXTRAS:"The Curious, Brilliant, Vanishing Mr. Feynman," series by Freakonomics Radio (2024).“Will a Covid-19 Vaccine Change the Future of Medical Research?” by Freakonomics Radio (2020).“Bad Medicine, Part 3: Death by Diagnosis,” by Freakonomics Radio (2016).

Episode Description:In this special edition of The New Chemist's Podcast, host David Ferguson brings you a three‑part journey:Around the World with Gary ArndtWe kick off with an in‑depth interview featuring award‑winning travel blogger, photographer, and podcaster Gary Arndt of Everything Everywhere Daily. Discover how Gary sold his home in 2007 to explore 190 countries, built a daily history podcast with nearly 2 million downloads, and turned storytelling into a global classroom ​.Bilingual Break: Langer & May in JapaneseNext, immerse yourself in a Japanese translation of highlights from Dr. Robert Langer and Dr. Matthew May's groundbreaking conversation. Whether you're strengthening your language skills or simply curious about how leading scientists share ideas across cultures, this segment bridges East and West.Pharmacokinetics FundamentalsFinally, sharpen your clinical toolkit with a clear, step‑by‑step primer on the fundamentals of pharmacokinetics. We'll unpack absorption, distribution, metabolism, and excretion—arming you with the core concepts every pharmacist and researcher needs.Tune in for an episode that spans continents, languages, and the science of drug movement through the body. Whether you're a travel enthusiast, a language learner, or a pharmacy professional, there's something here for everyone.

In this episode, I chatted with Dr. Kaitlyn Sadtler, who is pushing the boundaries of biomedical science. Co-hosted with HHMI Gilliam Fellow and ChemE PhD Candidate Sydney Floryanzia, we talk about their groundbreaking research, the twists and turns of their scientific journeys, and the power of collaboration in tackling big challenges.More on Dr. Sadtler, per the NIBIB:Kaitlyn Sadtler, Ph.D. joined NIBIB as an Earl Stadtman Tenure-Track Investigator and Chief of the Section for Immunoengineering in 2019. Prior to her arrival to the NIH, she completed a postdoctoral fellowship at the Massachusetts Institute of Technology with Daniel Anderson, Ph.D. and Robert Langer, Ph.D., focusing on the molecular mechanisms of medical device fibrosis. During her time at MIT, Dr. Sadtler was awarded an NRSA Ruth L Kirschstein Postdoctoral Fellowship, was listed on BioSpace's 10 Life Science Innovators Under 40 To Watch and StemCell Tech's Six Immunologists and Science Communicators to Follow. In 2018, she was named a TED Fellow and delivered a TED talk which was listed as one of the 25 most viewed talks in 2018. She was also elected to the 2019 Forbes 30 Under 30 List in Science, selected as a 2020 TEDMED Research Scholar, and received multiple other awards. Dr. Sadtler received her Ph.D. from the Johns Hopkins University School of Medicine where her thesis research was published in Science magazine, Nature Methods, and others. She was recently featured in the Johns Hopkins Medicine Magazine as an alumna of note. Dr. Sadtler completed her bachelor's degree summa cum laude at the University of Maryland Baltimore County, followed by a postbaccalaureate IRTA at the Laboratory of Cellular and Molecular Immunology at NIAID.

Today on the podcast, we are joined by Robert Langer, scientist, inventor and entrepreneur - and one of the most cited researchers in history, often called the “Edison of Medicine”. What makes Dr Langer special is that he is not only an academic but also an entrepreneur: turning frontier science into groundbreaking companies. Langer Lab's research has given rise to over 400 companies, and is also the co-founder of multiple companies, including Moderna, which discovered the COVID-19 vaccine.Dr Langer is one of nine Institute Professors at MIT - the highest honour that can be awarded to a faculty member. Langer's MIT research laboratory is the largest biomedical engineering lab in the world, with over $10 million in annual grants and over 100 researchers. He has written over 1,600 articles, which have been cited almost half a million times. Dr Langer has also received over 220 awards and served as Chairman of the FDA's Science Board.Dr Langer's work specialises in biotech fields of drug delivery systems and tissue engineering. He was the pioneer of delayed release medicine, and it was calculated his work had impacted an estimated two billion lives, helping those with cancer, burns, heart disease, spinal injuries and more - even before the Moderna Covid19 vaccine was developed.In this episode we talk about what scientific founders should watch out for, why getting patents are so critical, why you should follow your passion, why he thinks science is better than ever in the US, why he's excited by brains built on chips, if Attention Deficit Disorder makes him a better founder, and why failure makes you better.Building a purpose driven company? Read more about Giant Ventures at www.Giant.vc.Music credits: Bubble King written and produced by Cameron McLain and Stevan Cablayan aka Vector_XING. Please note: The content of this podcast is for informational and entertainment purposes only. It should not be considered financial, legal, or investment advice. Always consult a licensed professional before making any investment decisions.

The New Chemist's - 偉大な頭脳が出会う場所 - 科学の先駆者たち: 刺激的な会話が日本語で配信 ポッドキャストの説明: The New Chemist's Podcast のこの特別版では、科学、教育、イノベーションの世界からの魅力的な議論が日本語に翻訳されています。ゲイリー・メイ学長やロバート・ランガー博士などの先駆者たちとの会話に飛び込み、彼らの旅、画期的な貢献、そして科学者や教育者を目指す人々へのアドバイスを共有してください。このポッドキャストは、刺激的なストーリーを世界中の視聴者に届け、言語の壁を打ち破り、知識の交換を促進することを目的としています。 免責事項: このポッドキャストで表明された見解や意見は、ゲストスピーカーとホストの見解です。必ずしも関連組織の公式のポリシーや立場を反映するものではありません。このポッドキャストは情報提供と教育のみを目的としています。 --- Podcast Description: This special edition of The New Chemist's Podcast brings captivating discussions from the world of science, education, and innovation, now translated into Japanese. Dive into conversations with pioneers like Chancellor Gary May and Dr. Robert Langer as they share their journeys, groundbreaking contributions, and advice for aspiring scientists and educators. This podcast aims to make inspiring stories accessible to a global audience, breaking linguistic barriers and fostering knowledge exchange. Disclaimer: The views and opinions expressed in this podcast are those of the guest speakers and the host. They do not necessarily reflect the official policy or position of any affiliated organizations. This podcast is for informational and educational purposes only.

I got the opportunity to talk to Michael Langer, a well-known venture capitalist and investor in the biotech and health care industry, who is also the son of Moderna cofounder, Dr. Robert Langer. We talked about the investments he made, family investments, how to start a VC firm, challenges of the VC firm, and popular biotech trends.---------------------------------------------------Thanks to the sponsors:Audible: Use my link for a 30-day free trial: http://audibletrial.com/diamondgoat Newsly: https://newsly.me promo code to receive a 1-month free premium subscription: EARLYMORNING Libysn: https://libsyn.com promo code: DGDubby Energy: https://www.dubby.ggpromo code for 10% off: DIAMONDGOATOpus Clips:  https://www.opus.pro/?via=diamondgoat----------------------------------------------------------------------------------Listen on:Podcast website: https://www.spreaker.com/podcast/dg-early-morning-show--5943922Spotify: https://open.spotify.com/show/0EuhA6WyuerHtVAqcFrFeOPodcast YT channel clips: https://www.youtube.com/@dgearlymorningshowTiktok: @dgearlymorningshowApple Podcast: https://podcasts.apple.com/us/podcast/dg-early-morning-show/id1575451533Amazon Music: https://music.amazon.com/podcasts/f050b86c-1dad-4bc3-b12f-6aa5fa62438c Goodpods: https://goodpods.com/podcasts/dg-early-morning-show-211830RadioPublic: https://radiopublic.com/dg-earlymorning-show-WoML4rBreaker: https://www.breaker.audio/dg-early-morning-showReason: https://reason.fm/podcast/dg-earlymorning-show--------------------------------------Check out my other stuff:Instagram: @itzdiamondgoatTwitter: @lildiamondgoatMain YT channel: youtube.com/diamondgoatTiktok: @lildiamondgoatSoundcloud: @Lil DiamondgoatSpotify: @Lil DiamondgoatMerch store: https://diamondgoat.creator-spring.com

Send us a textDr. Richard Scranton, M.D., M.P.H., is the President of Global Product Development and the Chief Medical Officer of Lyndra Therapeutics ( https://lyndra.com/ ), a company pioneering long-acting oral therapies, designed to deliver medicine for up to a week or longer in an oral form. Dr. Scranton is responsible for advancing the company's proprietary LYNX™ drug delivery platform ( https://lyndra.com/platform/ ) and evolving and overseeing portfolio strategy, current and future product development from preclinical through commercialization, and external partnerships and alliances. Dr. Scranton has 20+ years of expertise in pharmaco-epidemiologic research, clinical epidemiology, health services research and clinical trials research.Prior to joining Lyndra, Dr. Scranton held roles with increasing responsibility at Pacira Pharmaceuticals, including Chief Medical Officer, where he led the global development and advancement of their non-opioid long-lasting injectable local anesthetic. Dr. Scranton also served as Chief Medical Officer at VeroScience, where his responsibilities included all aspects of clinical development, regulatory and pharmacovigilance of their investigational drugs in the metabolic disease and immunological domains. Dr. Scranton also has served as instructor in medicine at Harvard Medical School and associate physician in the division of aging at Brigham and Women's Hospital, associate medical director and research consultant for Phase V Technologies, assistant clinical professor of medicine at the Uniformed Services University of the Health Sciences and a senior research fellow at the Massachusetts Veterans Administration Epidemiology, Research and Information Center (MAVERIC).Dr. Scranton earned a Bachelor of Arts from the University of Tennessee and a Doctor of Medicine from the Quillen College of Medicine at Eastern Tennessee State University. He completed his internship and residency in internal medicine at the Naval Medical Center in Portsmouth, Va, and served as chief resident. He completed his Harvard General Medicine Fellowship and received a Master of Public Health from the Harvard School of Public Health. #RichardScranton #LyndraTherapeutics #LongActing #OralTherapies #Risperidone #Pharmacoepidemiology #MedicationAdherence #RobertLanger #BiochemicalEngineering #Schizophrenia #OpioidUseDisorder #PregnancyPrevention #Pharmacokinetics #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show

In this episode, titled "Honoring Innovation: A Norwegian Tribute to Kavli Prize Winner Dr. Robert Langer, Sc.D.—A Mentor to Our Founder (DJ Ferguson)," we present a Norwegian-language interview with Dr. Langer, celebrating his recent achievement as a co-recipient of the Kavli Prize for Nanoscience, along with other scientists. -- Note: The views of this podcast represent those of my guest(s) and I. Note: Purpose of these episodes- not at all, for advice or medical suggestions. These are aimed to provide support for peer pharmacists in training in educational and intellectually stimulating ways. Again, these are not at all for medical advice, or for medical suggestions. Please see your local state and board-certified physician, PA or NP, and pharmacist for medical advice and suggestions.

Robert Langer lyckades med vad som ansågs omöjligt: han fann ett sätt att transportera in stora läkemedelsmolekyler på rätt plats i kroppen med hjälp av smarta partiklar. Idag är han en av de mest citerade forskarna någonsin. Lyssna på alla avsnitt i Sveriges Radio Play. Han är kemiingenjören som istället för oljeindustrin valde sjukvården, och där kom hans kunskaper till enorm nytta. Hans upptäckter har hjälpt miljarder patienter i världen, inom allt från cancerbehandling till covidvaccin. Han har inte själv tagit fram läkemedlen, men de skulle vara fullständigt värdelösa utan hans smarta metoder för kontrollerad leverans till rätt ställe i kroppen, säger svenska professorn i nanoteknologi Maria Strömme.Vi möter Robert Langer på hans laboratorium vid MIT, Massachusetts Institute of Technology, strax utanför Boston, och hör om tiden då hela forskningsvärlden misstrodde och till och med hånade hans idéer, eftersom det han gjorde sågs som omöjligt.Programmet är en repris från maj 2024. Reporter: Björn Gunérbjorn.guner@sr.seProducent och programledare: Camilla Widebeckcamilla.widebeck@sr.se

Mandela Day 2024 Special: The New Student Pharmacist's Podcast in Afrikaans and English -- Om Mandela-dag te vier, beoog ons in hierdie episode om die onderhoude van Dr. Robert Langer, Sc.D. en dr. Emery Brown, MD, PhD in Afrikaans en Engels. Geniet die dubbele vertalings van beide onderhoude. -- Neem asseblief kennis dat die sienings van hierdie poduitsending dié van my gas(s) en ek verteenwoordig. Ons verwerp enige verlies op enige manier. Sien asseblief 'n mediese beroep wat deur die raad gesertifiseer is en staatsgeregistreer is vir advies en konsultasie. Dit is nie ontwerp om te dien as 'n plaasvervanger vir goeie mediese advies, voorstelle of konsultasies nie. Weereens, ons weier enige verlies op enige manier. --- Mandela Day 2024 Special: The New Student Pharmacist's Podcast in Afrikaans and English To celebrate Mandela Day, in this episode, we aim to present the interviews of Dr. Robert Langer, Sc.D. and Dr. Emery Brown, MD, PhD in Afrikaans and in English. Enjoy the dual translations of both interviews. -- Please note that the views of this podcast represent those of my guest (s) and I. We disclaim any loss in any way. Please see a medical professional who is board certified and state registered for advice and consultation. These are not designed to serve as a substitute for sound medical advice, suggestions or consultations. Again, we disclaim any loss in any way. ---

“Education is the most powerful weapon which you can use to change the world.” - Nelson Mandela -- Ukubhiyozela uSuku lukaMandela, kwesi siqendu, sijonge ukubonisa udliwano-ndlebe lukaGqirha Robert Langer, Sc.D. kunye noGqr. Emery Brown, MD, PhD kwisiXhosa nakwisiNgesi. Yonwabela iinguqulelo ezimbini zodliwano-ndlebe. Sikwasebenzisa umculo woMhobe waseMzantsi Afrika ngasemva. -- Nceda uqaphele ukuba iimbono zale podcast zimele ezo zendwendwe zam (s) kunye nam. Sikhupha nayiphi na ilahleko nangayiphi na indlela. Nceda ujonge ingcali yezonyango eqinisekisiweyo yebhodi kunye norhulumente obhalisiweyo ukufumana iingcebiso kunye nokubonisana. Ezi azenzelwanga ukuba zithathe indawo yengcebiso ephilileyo yezonyango, iingcebiso okanye iingcebiso. Kwakhona, sikhupha nayiphi na ilahleko nangayiphi na indlela. --- To celebrate Mandela Day, in this episode, we aim to present the interviews of Dr. Robert Langer, Sc.D. and Dr. Emery Brown, MD, PhD in Xhosa and in English. Enjoy the dual translations of both interviews. -- Please note that the views of this podcast represent those of my guest (s) and I. We disclaim any loss in any way. Please see a medical professional who is board certified and state registered for advice and consultation. These are not designed to serve as a substitute for sound medical advice, suggestions or consultations. Again, we disclaim any loss in any way. ---

The world of the very small is very different from the one we are familiar with. (Gold for instance turns red.) Chad Mirkin and Robert Langer's skills in crafting this bizarre micro-world into medical breakthroughs earned them the 2024 Kavli Prize in nanotechnology.

Dr. Robert S. Langer is the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT). Being one of the eight Institute Professors is the highest honor that can be awarded to a faculty member at MIT. Much of Bob's research is at the interface between materials and medicine. His lab has created nanoparticles and drug delivery systems, engineered tissues and organs for things like artificial skin for burn victims, and made organ-on-a-chip technology to help develop and test new drugs that may someday help patients. When he's not working, Bob enjoys spending time with his family, taking his kids to sporting events, lifting weights, and going on walks with his wife. He received his bachelor's degree in chemical engineering from Cornell University and his Sc.D. in chemical engineering from Massachusetts Institute of Technology. Afterwards, Bob worked as a postdoctoral fellow at the Children's Hospital Boston and at Harvard Medical School. He joined the faculty at MIT in 1978. Since then, Bob has accepted more than 220 major awards and honors, including the U.S. National Medal of Science, the U.S. National Medal of Technology and Innovation (he is one of 3 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, Hoover Medal, Dreyfus Prize in Chemical Sciences, BBVA Frontiers of Knowledge Award in Biomedicine, Balzan Prize, and the Dr. Paul Janssen Award. In 1998, he received the Lemelson-MIT prize, the world's largest prize for invention for being “one of history's most prolific inventors in medicine,” and he was inducted into the National Inventors Hall of Fame in 2006. He is an elected Fellow of the Institute of Medicine of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Sciences, and National Academy of Inventors, and the Royal Academy of Engineering. He has been awarded over 1,000 patents and has received 42 honorary doctorate degrees, including degrees from Harvard, Yale, Columbia, and Northwestern. In our conversation, he shares more about his life and science.

Robert Langer lyckades med vad som ansågs omöjligt: han fann ett sätt att transportera in stora läkemedelsmolekyler på rätt plats i kroppen med hjälp av smarta partiklar. Idag är han en av de mest citerade forskarna någonsin. Lyssna på alla avsnitt i Sveriges Radio Play. Han är kemiingenjören som istället för oljeindustrin valde sjukvården, och där kom hans kunskaper till enorm nytta. Hans upptäckter har hjälpt miljarder patienter i världen, inom allt från cancerbehandling till covidvaccin. Han har inte själv tagit fram läkemedlen, men de skulle vara fullständigt värdelösa utan hans smarta metoder för kontrollerad leverans till rätt ställe i kroppen, säger svenska professorn i nanoteknologi Maria Strömme. Vi möter Robert Langer på hans laboratorium vid MIT, Massachusetts Institute of Technology, strax utanför Boston, och hör om tiden då hela forskningsvärlden misstrodde och till och med hånade hans idéer, eftersom det han gjorde sågs som omöjligt. Reporter: Björn Gunérbjorn.guner@sr.seProducent och programledare: Camilla Widebeckcamilla.widebeck@sr.se

Robert Langer has co-founded dozens of companies, holds over a thousand patents, and is a pioneering figure in drug delivery and tissue engineering. Robert has solved a lot of problems, and is working on many more with his lab at MIT. But there is one big problem that has stuck with Robert his whole career: How do you get discoveries out of the lab and into the world?See omnystudio.com/listener for privacy information.

Dr. Omid Veiseh, Ph.D. ( https://profiles.rice.edu/faculty/omid-veiseh ) is Associate Professor in the Department of Bioengineering, CPRIT Scholar in Cancer Research and Director of the Biotech Launch Pad at Rice University ( https://biotechlaunchpad.rice.edu/ ), where he leads a research program aimed at engineering next-generation treatments for a wide range of human diseases by leveraging the latest techniques in synthetic biology, immuno-engineering, and materials science to develop innovative cell-based platforms for real-time production of biologics. He is also a serial entrepreneur who has co-founded Sigilon Therapeutics (Nasdaq:SGTX), Avenge Bio, Sentinel Bio, and Curada Bio. These companies collectively have attracted ~ US$500M in private and public investment capital. Dr. Veiseh received a dual Ph. D. in Materials Science & Engineering and Nanotechnology from the University of Washington. He completed his postdoctoral research with Prof. Robert Langer and Daniel G. Anderson at MIT and Harvard Medical School. Throughout his career, he has authored or co-authored more than 75 peer-reviewed publications, including those in Nature, Nature Biotechnology, Nature Materials, Nature Medicine, and Natural Biomedical Engineering. He is an inventor of more than 40 pending or awarded patents. Dr. Paul Wotton, Ph.D. ( https://biotechlaunchpad.rice.edu/paul-w ) is Rice Biotech Launchpad, Executive Director. Dr. Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham and is an experienced CEO, Board Member, named inventor and entrepreneur. He has extensive experience in strategic growth management, business transactions and product development. Dr. Wotton serves on the Board of Directors of Vericel Corporation (NASDAQ: VCEL), Cynata Therapeutics (ASX: CYP), Kytopen (Chairman), Combined Therapeutics and is a Co-Founder and Director of Avenge Bio., a clinical stage biotechnology company. Dr. Wotton was President and CEO of Ocata Therapeutics (NASDAQ:OCAT) until its acquisition by Astellas Pharma in 2016. Paul was named as a “Top 100 Innovation CEO” by World Biz Magazine and won the Ernst & Young Entrepreneur of the Year Regional (NJ) Life Sciences award in 2014. Support the show

Fan Yang, PhD is an Associate Professor at Stanford University with joint appointments in the Departments of Orthopaedic Surgery and Bioengineering joins OsteoBites to discuss her work on tissue engineering strategies for elucidating OS biology and drug discovery.Fan Yang, PhD is the founder and Director of Stanford Stem Cells and Biomaterials Engineering Laboratory, and also Co-director of Stanford NIH Biotechnology Training Program. Her research seeks to develop hydrogels with unique micro- and nano- scale properties to promote stem cell differentiation, tissue regeneration and immunomodulation, with a focus on musculoskeletal diseases. Her lab also harnesses biomaterials to create 3D cancer models with in vivo-mimicking phenotype and drug responses. Such 3D models could enable discovering novel druggable targets that would otherwise be missed using conventional 2D culture, and enable high-throughput drug screening with reduced cost and time than animal models. Prior to joining Stanford, Dr. Yang received her Ph.D. in Biomedical Engineering from Johns Hopkins University, and then completed a postdoctoral fellowship at MIT under Prof. Robert Langer. In recognition of her innovation, she has been recognized by numerous awards including Fellow of American Institute for Medical and Biological Engineering, MIT TR35 Global list honoree, National Science Foundation CAREER award, Young Investigator Award from Society for Biomaterials, Biomaterials Science Lectureship Award, Young Investigator award from Alliance for Cancer and Gene Therapy, Ellen Weaver Award by the Association for Women in Science, Baxter Faculty Scholar Award, the McCormick Faculty Award, Stanford Asian American Faculty Award, and the Basil O'Connor Starter Scholar Research Award, etc.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Abingworth has invested in Trodelvy development in a deal with Gilead, where one of the investment firm's startups will work with Gilead to expand the cancer drug's label. Cure Ventures has backed a cell therapy startup called Kenai Therapeutics targeting Parkinson's, with $82 million raised and chaired by Jeff Jonas, a former CEO of Sage Therapeutics. Former Turning Point executives have started a new startup with Blossomhill, focusing on cancer and autoimmune diseases and raising over $170 million in funding. Lindus Health, co-founded by a Moderna co-founder Robert Langer, is aiming to address challenges in contract drug research. Ginkgo has acquired Proof Diagnostics, founded by Feng Zhang, to gain gene editing tools for making genetic medicines.In other news, there is an inside look at biotech financing tools, a theory on protein chirality, settlement agreements in price-fixing cases, and upcoming webinars on omnichannel HCP engagement and tech talent recruitment in the life sciences industry. Biopharma Dive provides insights and news on biotech and pharma trends, covering topics such as clinical trials, FDA approvals, gene therapy, drug pricing, and research partnerships.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.UnitedHealth is facing an antitrust probe by the DOJ regarding potential anticompetitive effects. Despite challenges like high labor costs, UHS, a hospital operator, saw revenue growth in 2023. Veradigm is set to delist after missing a Nasdaq deadline. Nurse leaders report burnout and turnover in their roles. A ransomware attack at an urgent care provider may have exposed personal information of over 516,000 people. Healthcare Dive provides insights for healthcare leaders, including articles on AI implementation, social determinants of health, and healthcare data breaches, covering a wide range of topics such as hospitals, payers, health IT, government policies, finances, medical groups, and telehealth. Healthcare Dive is operated by Industry Dive, providing journalism and insights for decision-makers in competitive industries.Viatris pays $350 million to acquire two drugs from Idorsia for heart attacks and lupus in phase 3 testing. Ginkgo acquires gene editing tools through the buyout of Proof Diagnostics, founded by Feng Zhang. Incannex reports that psilocybin therapy reduced anxiety in a small study. Women's health company Obseva plans to wind down operations and lay off staff. Viking's obesity drug showed promising results in a phase 2 trial, potentially rivaling drugs from Eli Lilly and Novo Nordisk. The rise of obesity drug treatments is reshaping the pharma industry with significant advancements and changes, as companies make strategic moves to enhance their portfolios and address unmet medical needs.Gatorade has unveiled Gatorade Water, their first unflavored water product, with a digital-heavy marketing campaign focused on wellness. Estee Lauder's marketing mix modeling use was discussed at the eTail Palm Springs conference, showcasing their balance between brand and performance marketing. Dick's Sporting Goods has enlisted Kathryn Hahn and Will Arnett for an ad campaign highlighting e-commerce convenience. Food and beverage brands are putting a modern spin on retro packaging to appeal to consumers' emotions. Mod Op has acquired RTO+P for more creative firepower in a competitive market. Marketing Dive explores mobile messaging's influence on consumer behavior in 2024, as well as upcoming events and industry news.The recent awarding of Johnson & Johnson's Dr. Paul Janssen Award for Biomedical Research to MIT professor and Moderna co-founder Robert Langer is discussed in the text, recognizing his impactful innovations in drug delivery. Langer's work in nanoparticle drug delivery has led to advancements in biopharma, particularly in the technology behind mRNA vaccines. The text also highlights Langer's role as a scientific advisor to a new CRO aiming to improve clinical trials through technology. Additionally, it addresses the staffing challenges faced by CROs since the pandemic and explores strategies for retaining talent in the research industry, emphasizing the importance of adapting to new technologies and approaches to enhance efficiency in clinical trials and improve patient care.

Welcome to The Daily Wrap Up, a concise show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (12/27/23). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v4147wt","div":"rumble_v4147wt"}); Video Source Links (In Chronological Order): Pathologist Arne Burkhardt Final Interview - Revealing the Grave Dangers of mRNA Vaccines (24) LastAmericanVagabond on X: "Pathologist Arne Burkhardt Final Interview - Revealing the Grave Dangers of mRNA Vaccines https://t.co/do3l2TgwNP" / X New Tab (63) LastAmericanVagabond on X: "I discussed this in April of this year. The simple fact that this is being covered shows a deliberate effort to hide this from us. https://t.co/JquA0zPzPV "Gates/WEF-Backed Edible Food Coating Already In Use"" / X Gates/WEF-backed Edible Food Coating Already In Use, Cloud-Seeding, Hypocrisy & The CIA New Tab Derrick Broze Interview - Impending Future Of Social Credit, Social Impact Investing & Digital IDs Central Bank Digital Currency (CBDC) - Virtual Handbook (64) Derrick Broze on X: "@UNDPDigital @UNDP @DPGAlliance @LetsCoDevelop @gatesfoundation It's important for you to understand we see through the propaganda. We will not stand on the sidelines and watch you cram digital ID down our throats. We understand that some of you mean well, but you must respect our bodily autonomy and right to be free of the digital prison." / X Implementing digital public infrastructure, safely and inclusively - 50-in-5 Screen Shot 2023-12-27 at 4.27.12 PM.png (2480×868) NYU School of Law Warns Digital ID "Paving a Digital Road to Hell" (61) Wide Awake Media on X: "Dutch political commentor, Eva Vlaardingerbroek (@EvaVlaar): Vaccine passports were a precursor for CBDC and digital ID, which will be used to dictate the parameters for participation in society, including the imposition of personal carbon allowances. "We're gonna walk straight… https://t.co/Dz6eSgfyj4" / X Sesame Credit: China's Creepy New Social Engineering Experiment - The Corbett Report (61) The Investigative Examiners on X: "@JamesMelville Indeed https://t.co/Sj8a933wDv" / X People Filmed Tearing Down Posters of Israeli Hostages (29) StopAntisemitism (@StopAntisemites) / X Pro-Palestine Activist Gets Instant Karma When She Tries Ripping Down Posters Of Missing Israelis | The Daily Caller #ID2020 Defector Speaks On “Techno-Solutionism" With Immunity Passports & The Vaccine Deception 2019-2022_roadmap_en.pdf main.pdf (87) PC on X: "Bill Gates provided $14m of initial funds for biotech company 'Particles for Humanity' which is building an "ON-PATIENT MEDICAL RECORD EMBEDDING VACCINATION INFORAMTION INTO SKIN" and is run by the co-executor of Epstein's will Boris Nikolic and Moderna co-founder Robert Langer. https://t.co/ZlDCcpOT9f" / X Particles for Humanity | Bill & Melinda Gates Foundation Particles for Humanity static1.squarespace.com/static/5c17b41b4cde7a73c4203f65/t/5c534ac57817f7cd1cea886f/1548962519787/JP-Morgan-Presentation-190129.pdf Wayback Machine Storing medical information below the skin's surface | MIT News | Massachusetts Institute of Technology Bob Langer The Coronavirus "Common Denominator" Tied To Charles Lieber ...

In medicine, failure can be catastrophic. It can also produce discoveries that save millions of lives. Tales from the front line, the lab, and the I.T. department. RESOURCES:Right Kind of Wrong: The Science of Failing Well, by Amy Edmondson (2023)."Reconsidering the Application of Systems Thinking in Healthcare: The RaDonda Vaught Case," by Connor Lusk, Elise DeForest, Gabriel Segarra, David M. Neyens, James H. Abernathy III, and Ken Catchpole (British Journal of Anaesthesia, 2022)."Dispelling the Myth That Organizations Learn From Failure," by Jeffrey Ray (SSRN, 2016)."A New, Evidence-Based Estimate of Patient Harms Associated With Hospital Care," by John T. James (Journal of Patient Safety, 2013).To Err is Human: Building a Safer Health System, by the National Academy of Sciences (1999)."Polymers for the Sustained Release of Proteins and Other Macromolecules," by Robert Langer and Judah Folkman (Nature, 1976).EXTRAS:"How to Succeed at Failing," series by Freakonomics Radio (2023)."Will a Covid-19 Vaccine Change the Future of Medical Research?" by Freakonomics Radio (2020)."Bad Medicine, Part 3: Death by Diagnosis," by Freakonomics Radio (2016).

Dans cet épisode, nous discutons de certains articles du Dr Robert Langer (~ 1 561 articles) basés sur des fourchettes par centaines, en années et par ordre croissant. Grâce à l'utilisation d'outils logiciels, de Google Scholar et d'autres ressources, cette revue audio a été composée.--Lien vers le Dr Robert Langer, Sc.D. Profil Google Scholar de :https://scholar.google.com/citations?user=5HX--AYAAAAJ--Pour célébrer le travail accompli par le Dr Langer et ses réalisations en matière d'administration de médicaments. Une liste reprenant certaines de ses citations a été utilisée, à savoir 1561 (mille cinq cent soixante et une) citations. Si vous souhaitez trouver les citations dont nous discuterons, vous pouvez utiliser Google Scholar, dresser une liste de ses citations où il est répertorié comme auteur, les classer par années, puis en utilisant le thème, vous pouvez trouver les articles pertinents pour le sujet. thèmes qui seront abordés dans cet épisode.Certainement un épisode à écouter !Les références incluent : Google Scholar ; De nombreux articles ; (OpenAI, 2023) Hosted on Acast. See acast.com/privacy for more information.

Dans cet épisode, nous discutons de certains articles du Dr Robert Langer (~ 1 561 articles) basés sur des fourchettes par centaines, en années et par ordre croissant. Grâce à l'utilisation d'outils logiciels, de Google Scholar et d'autres ressources, cette revue audio a été composée. -- Lien vers le Dr Robert Langer, Sc.D. Profil Google Scholar de : https://scholar.google.com/citations?user=5HX--AYAAAAJ -- Pour célébrer le travail accompli par le Dr Langer et ses réalisations en matière d'administration de médicaments. Une liste reprenant certaines de ses citations a été utilisée, à savoir 1561 (mille cinq cent soixante et une) citations. Si vous souhaitez trouver les citations dont nous discuterons, vous pouvez utiliser Google Scholar, dresser une liste de ses citations où il est répertorié comme auteur, les classer par années, puis en utilisant le thème, vous pouvez trouver les articles pertinents pour le sujet. thèmes qui seront abordés dans cet épisode. Certainement un épisode à écouter ! Les références incluent : Google Scholar ; De nombreux articles ; (OpenAI, 2023)

En este episodio analizamos algunos artículos del Dr. Robert Langer (~1561 artículos) basados en rangos por cientos, en años y en orden ascendente. Con el uso de herramientas de software, Google Scholar y otros recursos, se compuso esta reseña de audio. -- Enlace al Dr. Robert Langer, Sc.D. Perfil de Google Scholar: https://scholar.google.com/citations?user=5HX--AYAAAAJ -- En una celebración del trabajo que ha realizado el Dr. Langer y los logros que ha logrado en la administración de medicamentos. Se utilizó una lista con algunas de sus citas, a saber, 1561 (mil quinientas sesenta y una) citas. Si desea encontrar las citas que discutiremos, puede usar Google Scholar, redactar una lista de sus citas donde figura como autor, ordenarlas por años y luego, usando el tema, puede encontrar los artículos relevantes para el tema. temas que se discutirán en este episodio. ¡Definitivamente un episodio que vale la pena escuchar! Las referencias incluyen: Google Scholar; Numerosos artículos; (OpenAI, 2023)

In this episode we discuss some Dr. Robert Langer's articles (~1561 articles) based off of ranges by the hundred(s), in years and in ascending order. With the use of software tools, Google Scholar and other resources, this audio review was composed. -- Link to Dr. Robert Langer, Sc.D. 's Google Scholar Profile: https://scholar.google.com/citations?user=5HX--AYAAAAJ -- In a celebration of the work Dr. Langer has done and the accomplishments he has made in drug delivery. A list with with some of his citations was used, namely 1561 (one thousand five hundred and sixty-one) citations . If you want to find the citations which we will discuss, you can use Google Scholar, compose a list of his citations where he is listed as an author, arrange them by years, and then using the theme you can find the papers relevant to the themes which will be discussed in this episode. Definitely an episode worth listening to! References include: Google Scholar; Numerous Articles; (OpenAI, 2023)

In this episode, we combine a wealth of information from pioneers in pharmacology & drug design ( Dr. L. Jungheim ( Former Mentor) & Dr. L.C. Campeau (Associate Vice President, Head of Small Molecule Process R&D at Merck) , bioengineering ( Dr. Robert Langer,Sc.D. - MIT Institute Professor & Co-Founder of Moderna) and designing bioisosteres ( Dr. Kevin Brown, James F. Jackson Professor of Chemistry, IU-Bloomington) ), to present salient and key insights on careers in those areas and advice and skills needed to do well in those fields. Definitely an episode worth listening to! The order of the interviews: 1. Dr. Robert Langer, Sc.D. 2. Dr. L.C. Campeau, Ph.D. 3. Dr. K. Brown, Ph.D. 4. Dr. L. Jungheim, Ph.D. -- Note: The views on this podcast represent those of my guest(s) and I.

Today's guests is Dr Robert Langer – a chemical engineer, scientist, entrepreneur, inventor and the most cited engineer in history - specializing in the biotechnology fields of drug delivery systems and tissue engineering. He is also the co-founder of Moderna a pharmaceutical and biotechnology company that focuses on RNA therapeutics, primarily mRNA vaccines which was used globally for Covid-19.Bob Langer has received over 200 major awards– one of just four individuals to have received both the United States National Medal of Science and the United States National Medal of Technology and Innovation. He also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, and the Queen Elizabeth Prize for Engineering, among many othersIn this conversation, we discuss how he fell in love with science, what discoveries led to his pioneering work in tissue engineering and drug delivery, and what it takes to positively impact billions of lives. We also touch on anti-vaxxers, what it's like for scientists when misinformation rules social media and how rejection is par for the course for a scientist.I honestly think this is one of the most important conversations I have had on this podcast so please do enjoy.Bob Langer at MITDanielle on Twitter @daniellenewnham and  Instagram @daniellenewnham   / Newsletter   

Welcome to the Danielle Newnham Podcast where I interview tech founders and innovators to learn the inspiring, human stories behind the game-changing tech we use every day.I know I probably say this every series but Series 10 might be my most favourite yet and I really can't wait to share it with you! Upcoming guests this series include Simon Peyton Jones – Engineering Fellow at Epic Games, previously researcher at Microsoft Research in Cambridge, and one of the designers behind the Haskell programming language. We also have Robert Langer - chemical engineer, scientist, entrepreneur and, inventor. Robert is the most cited engineer in history and is also a prolific entrepreneur, having founded more than 40 biotech companies including Moderna… which you may have heard of.We also have Sarah Hamburg (a neuroscientist working in neuro-inspired computing and AI), Ian Livingstone – video game pioneer and co-founder of Games Workshop which launched Dungeons & Dragons in Europe, and is behind the cult-like Warhammer game, among many others. I will also be talking to Mike Slade (strategic advisor to Steve Jobs), and Kate Zernike (a Pulitzer-Prize winning reporter and author of The Exceptions: Nancy Hopkins, MIT and the Fight For Women in Science, and many more.So, as always, if you want to be the first to hear these episodes - please do make sure you subscribe to the Danielle Newnham Podcast wherever you get your podcasts from and I look forward to sharing these inspiring conversations with you over the coming weeks.Enjoy. 

In this episode of " "Lecture-casts"- A Podcast Lecture Series in General Chemistry", we present the interview with Dr. Robert Langer, Sc.D., MIT Institute Professor and Co-Founder of Moderna. This interview is remixed to be noise cancelling, and presented in English first, and then in Spanish.-----Transcript of Interview with Dr. Langer, Sc.D.https://thenewchemistpublications.pubpub.org/pub/alinjkww/release/2 Learn more about your ad choices. Visit megaphone.fm/adchoices Hosted on Acast. See acast.com/privacy for more information.

In this inspiring episode of " The New Chemist's Podcast" , we re-air the interview with Dr. Robert Langer, Sc.D., MIT Institute Professor and Co-Founder of Moderna. This interview is remixed to be noise cancelling, and presented in English first, and then in Spanish. --- Transcript of Interview with Dr. Langer, Sc.D. https://thenewchemistpublications.pubpub.org/pub/alinjkww/release/2

In this episode of "Lecture-casts"- A Podcast Lecture Series on General Chemistry", we are re-airing an interview with Dr. Robert Langer, Sc.D., and providing a translation of this great interview in Swedish.----Interview Transcript:https://thenewchemistpublications.pubpub.org/pub/alinjkww/release/2 Learn more about your ad choices. Visit megaphone.fm/adchoices Hosted on Acast. See acast.com/privacy for more information.

In this episode of "The New Chemist's Podcast", we are re-airing an interview with Dr. Robert Langer, Sc.D., and providing a translation of this great interview in Swedish. ---- Interview Transcript: https://thenewchemistpublications.pubpub.org/pub/alinjkww/release/2

How might engineering improve cancer outcomes in the next decade? What's the future of tech in hospitals? Why did fellow scientists laugh derisively when Moderna was developing their COVID-19 vaccine?Roma Agrawal hosts two engineers have been key in fighting back against the recent pandemic: Professor Rebecca Shipley, and Dr. Robert Langer, co-founder of Moderna and recipient of the Queen Elizabeth Prize for Engineering in 2015.Hear new episodes of Create The Future - conversations about how to rebuild the world better - every other Friday.Follow us on Twitter, Instagram, and Facebook for more. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Lexman discusses variant genes and how they might lead to new treatments for hellebores. He also chats with Robert Langer, a world-renowned scientist who has studied hellebores extensively.

In this episode, we highlight through the use of a video episode, the previous conversation between our producer, Mr. David Ferguson, and one of his guests on The New Chemist's Podcast-- Dr. Robert Langer, MIT Institute Professor and Co-Founder of Moderna. Learn more about your ad choices. Visit megaphone.fm/adchoices Hosted on Acast. See acast.com/privacy for more information.

I invited Dr. Robert Langer, biotech billionaire and one of the twelve Institute Professors at the MIT, on the podcast. He is a cofounder of multiple biotech companies including Moderna. In this episode, we talked about a lot of interesting topics, like making artificial organs, startup and business advice, biotech's future, innovative drug delivery systems, and his new vitamin company, Vitakeys.  ----------------------------------------- Thanks to the sponsors/ partners: Newsly: https://newsly.mepromo code to receive a 1-month free premium subscription: EARLYMORNING  Anchor https://anchor.fm Libysn https://libsyn.compromo code: DG Dubby Energy https://www.dubby.ggpromo code for 10% off: DIAMONDGOAT spikeview https://www.spikeview.comhttps://www.instagram.com/spikeview ---------------------------------------------------------------------------------- Listen on: Podcast website: https://anchor.fm/diamondgoat Spotify: https://open.spotify.com/show/0EuhA6WyuerHtVAqcFrFeO Google Podcast: https://www.google.com/podcasts?feed=aHR0cHM6Ly9hbmNob3IuZm0vcy80NzE4MzM5MC9wb2RjYXN0L3Jzcw== RadioPublic: https://radiopublic.com/dg-earlymorning-show-WoML4r Breaker: https://www.breaker.audio/dg-early-morning-show Podcast YT channel clips: https://www.youtube.com/@dgearlymorningshow Reason: https://reason.fm/podcast/dg-earlymorning-show Apple Podcast: https://podcasts.apple.com/us/podcast/dg-early-morning-show/id1575451533 Amazon Music: https://music.amazon.com/podcasts/f050b86c-1dad-4bc3-b12f-6aa5fa62438c Tiktok: @dgearlymorningshow -------------------------------------- Check out my other stuff: Instagram: @itzdiamondgoat Twitter: @lildiamondgoat Main YT channel: youtube.com/diamondgoat Tiktok: @lildiamondgoat Soundcloud: @Lil Diamondgoat Spotify: @Lil Diamondgoat Merch store: https://diamondgoat.creator-spring.com --- Support this podcast: https://podcasters.spotify.com/pod/show/diamondgoat/support

In this podcast, you will hear a keynote fireside discussion with Dr Robert Langer, MIT, and Dr Ester Caffarel-Salvador, Chiesi USA, from the 2022 PODD Conference regarding current projects in the Langer Lab, how COVID affected the lab's dynamics and collaborations, challenges in the drug delivery space, and exciting technologies in the pipeline,  To learn more about the PODD Conference, please visit PODDConference.com.  

We have remixed a previous interview with on of the most cited engineers in history, and a very kind, intelligent and impactful scientist, Co-Founder of Moderna, and MIT Institute Professor, Dr. Robert Langer, Sc.D.. Hopefully this encourages people to “Dream Big Dreams” and work smart and hard on ideas that help the wider society and the world advance!

Lexman Artificial interviews Robert Langer about his work on stragglers and incitation in arpeggiation.

Lexman and Robert Langer geek out over chalk invention. Lexman interviews the inventor of chalk, Dr. Debra W. Soh, about her product and the future of the chalkboard.

Today's guest is a renowned chemical engineer and 2015 Queen Elizabeth Prize for Engineering Laureate, Dr Robert Langer. A pioneer in biotechnology, including large molecule controlled drug delivery and nanotechnology, Langer is also regarded as the founder of tissue engineering. His work is the basis for—among countless other innovations—long-lasting treatments for brain cancer, prostate cancer, endometriosis, schizophrenia, diabetes, and the drug-coated cardiovascular stents that alone have benefited 10 million patients.In this episode of the Create the Future podcast, we speak with Dr Langer about his engineering journey, from career setbacks to the launch of over 40 biotech companies. We hear how his 2015 QEPrize-winning technology enabled Moderna's COVID-19 mRNA vaccine, explore the field of tissue engineering, and discuss why multidisciplinary teams are essential for innovation.New episodes of Create the Future: An Engineering Podcast every other Tuesday. www.qeprize.org/podcastsFollow @qeprize on Twitter, Instagram, and Facebook See acast.com/privacy for privacy and opt-out information.

Renowned chemical engineer Robert Langer, a pioneer in the development of the mRNA vaccines used to help combat COVID-19, will speak Wednesday, June 1, at 7:30 p.m. in the Nott Memorial. His talk, “From Nanotechnology to mRNA Vaccines: How Overcoming Skepticism and Barriers Led to New Cancer Treatments and Ways to Tackle a Global Health Challenge,” is free and open to the public.

Todos los años se registran miles de terremotos y hay más de un millar de volcanes activos. Algunos cercanos como el de la isla de La Palma y otros más lejanos como el volcán submarino de Tonga, cuya explosión el pasado 15 de enero liberó una energía equivalente a entre 4 y 18 megatones de TNT, más de cien veces la bomba atómica de Hiroshima. Esta intensa actividad es una muestra de que nos encontramos en un planeta vivo donde continuamente se está formando y destruyendo la corteza terrestre. Unos fenómenos que explica la teoría de la Tectónica de placas. Hemos entrevistado a José Antonio Álvarez Gómez, doctor en Geología y profesor en la Universidad Complutense. Carmen Girona nos ha informado de unos aceites vegetales líquidos (oleogeles) desarrollados en el Instituto de Investigación en Ciencias de la Alimentación del CSIC, que podrían sustituir a las grasas saturadas empleadas en la producción de alimentos. Con testimonios de Marta Martínez Sanz. Katalyn Karikó, Robert Langer y Drew Weissman han sido galardonados con el premio Fronteras en Biología y Biomedicina de la Fundación BBVA por haber creado dos tecnologías que unidas han impulsado las terapias de ARN mensajero, abriendo la puerta al desarrollo de vacunas y tratamientos contra múltiples enfermedades. Con Lluis Montoliu nos hemos acercado a esta técnica tan prometedora. Álvaro Martínez del Pozo nos ha hablado una intoxicación alimentaria, la listeriosis, y más concretamente de la toxina (listeriolisina) que producen las bacterias del género Listeria. El deshielo de los polos está abriendo la posibilidad de nuevas rutas por el Ártico con todo lo que eso implica como nos ha explicado Javier Cacho. En nuestra sección "Mujer y ciencia", Eulalia Pérez Sedeño ha trazado la biografía de Marie Colinet, una cirujana y comadrona suiza que vivió en los siglos XVI y XVII. Mejoró la técnica de la cesárea y tuvo la idea de usar un imán para extraer metal incrustado en un ojo humano. Hemos reseñado los libros "El primate que cambió el mundo. Nuestra relación con la naturaleza desde las cavernas hasta hoy", de Alex Richter-Boix (GeoPlaneta); "Las diez claves de la realidad" de Frank Wilczek (Crítica); y "El problema de la consciencia", de Miguel Ángel Sebastián (Cátedra). Escuchar audio

Robert Langer and Kathryn Whitehead talk with Senior Editor Markus Elsner about drug delivery methods and their applications within a wide range of therapeutic modalities. See acast.com/privacy for privacy and opt-out information.

Listen to our conversation with Dr. Robert Langer, David H. Koch Institute Professor at MIT, on the race to produce the Moderna vaccine, how he evaluates startup ideas at his lab, and what it really takes to produce a high quality patent.

Carl Schoellhammer is co-founder and president of Suono Bio, a preclinical-stage company focused on the ultra-rapid delivery of novel therapeutics to the gastrointestinal (GI) tract. This technology is super cool - essentially using ultrasound devices to deliver drugs through the skin. This is game-changing for people with, for instance, colitis and other inflammatory issues in their gut. We talk about the technology and its future capabilities, as well as how Carl and his partner Gio developed the invention and spun it off into a company. It's this cross-disciplinary collaboration (Gio a gastroenterologist, Carl a chemical engineer with experience in pharma) that allowed them to solve the problem - a feature of Robert Langer's lab which is emulated in research labs around the world. Carl was a post-doc in Langer Lab along with Gio and he describes the process of discovering the invention and working with Bob and MIT to commercialize it. For those who don't know, Bob Langer is the most cited engineer in history. He's a modern day Thomas Edison. He's published/developed something like 800 papers, 500 patents, thousands of researchers have passed through his lab, he's spun off dozens of startup companies, 100's of licensing deals and more. It was really interesting to hear what it's like to work in Bob's lab and co-found a company with him. Just read this quote from Bob on the website of one of their investors, The Engine - “Suono Bio exemplifies what I've observed is required for a successful company: a platform technology with potentially broad utility, proof that it works in animal models, powerful patents, and publications in top-tier journals,” says Professor Langer. “The ability to deliver unformulated therapeutics with this technology is a tremendous achievement in the field of drug delivery and has potential for widespread applicability in a range of diseases. Carl is highly driven, extremely brilliant, even by MIT standards, and really wants to make a difference in the world.” More about Carl Carl received his B.S. from the University of California, Berkeley in Chemical Engineering, and completed his Ph.D. and postdoctoral training in the lab of Professor Robert Langer at MIT. His work has been published in Science Translational Medicine and Gastroenterology, and has been featured by Forbes, Popular Science, CNET, and The Atlantic, among others. He was the recipient of the 2015 Lemelson-MIT National Collegiate Inventors Prize, the 2016 National Collegiate Inventors Competition top prize, and was named a Forbes 30 Under 30 in Healthcare. Find Carl on LinkedIn and Twitter More about Suono Suono Bio is developing a platform technology to enable the ultrasonic, targeted delivery of drugs and macromolecules, proteins, DNA, RNA, and even the gene-editing tool CRISPR, directly to the gastrointestinal (GI) tract, their first use case. This enables them to “push” virtually any therapeutic class, including temperamental molecules, like nucleic acids, directly into cells with astounding efficacy and accuracy, affecting historically "undruggable" targets. They harness the power of ultrasound-induced cavitation to achieve this delivery and are applying it to creating new treatments for a variety of diseases, starting with inflammatory conditions. Learn more about Suono on their website. Join the Bountiful community today and realize your power to save the world. Don't forget to follow us on Twitter and LinkedIn if you haven't already.